BioSpace News Archive

Jaguar Health, Inc. (NASDAQ:JAGX) (“Jaguar” or the “Company”) announced today that a preclinical study evaluating the effects of crofelemer (Mytesi®) in providing symptomatic relief of diarrhea associated with the irreversible pan-HER tyrosine kinase inhibitor (TKI) neratinib (Nerlynx®) is being presented as an e-poster at the American Association for Cancer Research Virtual Annual Meeting II,

ENDRA Life Sciences Inc. (''ENDRA’’) (NASDAQ:NDRA), a pioneer of Thermo Acoustic Enhanced UltraSound (TAEUS™), has recently been issued Patents 10,682,059 and 10,687,789 from the United States Patent and Trademark Office.

Kadmon Holdings, Inc. (NYSE:KDMN) today announced that the first patient has been dosed in a Phase 1 clinical trial evaluating KD033, an anti-PD-L1/IL-15 fusion protein, in patients with metastatic or locally advanced solid tumors.

Fusion Pharmaceuticals Inc., a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines, announced the pricing of its initial public offering of 12,500,000 common shares at a public offering price of $17.00 per share.

- FINTEPLA® significantly and substantially reduced convulsive seizure frequency in patients whose seizures were not adequately controlled on other medications, as observed in two phase 3 placebo-controlled clinical trials - Commercial launch planned for July 2020 - Zogenix to host an investor call tomorrow, June 26, at 8:30 AM ET / 5:30 AM PT [25-June-2020]

The American Urological Association and the Sexual Medicine Society of North America will be releasing a new clinical practice guideline to aid in the diagnosis and treatment of ejaculatory disorders in men.

Multi-center trial to evaluate the safety and efficacy of pelareorep-anti-PD-1 combination therapy in triple-negative breast cancer, an indication of continued unmet medical need

Company expands program to award 25 grants totaling $125,000 to fund nonprofit, community-based organizations supporting individuals with sickle cell disease and beta-thalassemia

Enhanced range of volumes and design features will support expanded use in both cell therapy drug development and early drug discovery

At the American Association for Cancer Research 2020 Virtual Annual Meeting II, AnchorDx presented a poster unveiling a new generation of ctDNA methylation detection technology, named Aurora, for multi-cancer screening, titled Toward the Development of a $100 Screening Test for Six Major Cancer Types.